期刊文献+

黄豆苷元半固体骨架型胶囊处方的初步研究 被引量:4

Formulation of Daidzein Semisolid Matrix Capsules
原文传递
导出
摘要 目的:采用半固体骨架技术提高黄豆苷元的体外溶出度。方法:采用熔融法制备黄豆苷元半固体骨架胶囊,比较不同载体材料聚氧乙烯(40)硬脂酸酯(S-40)、泊洛沙姆、聚乙二醇(PEG)4000,不同含药量(2%、4%、6%),表面活性剂吐温-80不同用量(15%、20%、25%、30%)对其体外溶出度的影响并与市售胶囊进行比较。结果:上述3种影响因素中溶出度较优的选择为采用S-40为载体,含药量为2%,吐温-80用量20%。所制胶囊体外溶出速率快于市售胶囊。结论:半固体骨架技术能够提高难溶性药物黄豆苷元的体外溶出度。 OBJECTIVE: To enhance the dissolution of daidzein by semisolid matrix technique. METHODS : Semi - solid matrix capsules were prepared by fusion method. The influences of different carriers including polyoxyethylene (40), stearate (S- 40), poloxamer, and polyethylene glycol (PEG) 4000, drug contents (2%, 4%, and 6%), contents of surfactants- tween 80 (15%, 20%, 25%, and 30% ) on the dissolution in vitro were analyzed and which were compared with the common capsules sold in the market. RESULTS: Optimal dissolution was obtained when the condition of the above three factors was as follows: the carrier was S- 40; the drug content = 2%, and the content of twieen- 80 : 20%. The dissolution rate of the capsule prepared in this condition was higher than that of the common capsule. CONCLUSION: The in vitro dissolution rate of daidzein (which is hard to dissolve) could be enhanced by semi- solid matrix technique.
出处 《中国药房》 CAS CSCD 北大核心 2007年第22期1716-1718,共3页 China Pharmacy
关键词 黄豆苷元 半固体 胶囊 溶出度 Daidzein Semisolid Capsule Dissolution
  • 相关文献

参考文献7

二级参考文献17

  • 1王晓青,傅静.葛根的药理作用研究进展(综述)[J].北京中医药大学学报,1994,17(3):39-41. 被引量:81
  • 2王昕,姚崇舜,陈济民.葛根黄豆甙元结构改造及其构效关系[J].沈阳药科大学学报,1996,13(4):300-306. 被引量:8
  • 3李庆福 红庆娥.α-氨基异黄酮化合物的合成[J].药学学报,1987,22(9):655-655. 被引量:1
  • 4曾贵云 周远鹏 等.葛根的药理研究[J].中华医学杂志,1974,(5):265-270. 被引量:8
  • 5Baykara T, Yüksel N. The preparation of prolonged acion formulations in the form of semisolid matrix into hard gelatin capsules of oxprenolol Ⅱ. Thixocap method[J].Drug Dev Ind Pharm,1992,18(2):233-243. 被引量:1
  • 6Jose G R. Controlled release pharmaceutical composition[P]. US:6491950 B1, 2002-12-10. 被引量:1
  • 7Jose G R, Josephine D, Saul A, et al. Controlled release pharmaceutical composition[P]. US:6524615 B2,2003-02-25. 被引量:1
  • 8Walker S E, Bedford K, Eaves T. Improvements in and relating to pharmaceutical preparations in solid unit dosage form[P]. GB:1572226,1980-07-30. 被引量:1
  • 9Rowley G, Hawley A R, Dobson C L, et al. Rheology and filling characteristics of particulate dispersions in polymer melt formulations for liquid filled hard gelatin capsules[J]. Drug Dev Ind Pharm, 1998, 24(7):605-611. 被引量:1
  • 10Thakkar A L, Gibson L L, Grove B. Orally administerable sustained release pharmacerutical formulations[P]. US:4797286,1989-01-10. 被引量:1

共引文献43

同被引文献21

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部